Xywav™ (calcium, magnesium, potassium, and sodium oxybates) – New orphan drug approval
July 22, 2020 - Jazz Pharmaceuticals announced the FDA approval of Xwav (calcium, magnesium, potassium, and sodium oxybates), for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Top